362 related articles for article (PubMed ID: 23268703)
21. A critical overview on ticagrelor in acute coronary syndromes.
Navarese EP; Buffon A; Kozinski M; Obonska K; Rychter M; Kunadian V; Austin D; De Servi S; Sukiennik A; Kubica J
QJM; 2013 Feb; 106(2):105-15. PubMed ID: 23097390
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.
Teng R
Clin Pharmacokinet; 2012 May; 51(5):305-18. PubMed ID: 22489610
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia.
Rosa GM; Bianco D; Valbusa A; Massobrio L; Chiarella F; Brunelli C
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1491-1502. PubMed ID: 27715344
[TBL] [Abstract][Full Text] [Related]
24. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
Packard KA; Campbell JA; Knezevich JT; Davis EM
Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
[TBL] [Abstract][Full Text] [Related]
25. A new era for antiplatelet therapy in patients with acute coronary syndrome.
Dib C; Hanna EB; Abu-Fadel MS
Am J Med Sci; 2010 Nov; 340(5):407-11. PubMed ID: 20818228
[TBL] [Abstract][Full Text] [Related]
26. Review of ticagrelor in the management of acute coronary syndromes.
Burgess S; Mallard TA; Juergens CP
Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1315-25. PubMed ID: 22924796
[TBL] [Abstract][Full Text] [Related]
27. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
[TBL] [Abstract][Full Text] [Related]
28. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study.
Qaderdan K; Ishak M; Heestermans AA; de Vrey E; Jukema JW; Voskuil M; de Boer MJ; van't Hof AW; Groenemeijer BE; Vos GJ; Janssen PW; Bergmeijer TO; Kelder JC; Deneer VH; ten Berg JM
Am Heart J; 2015 Nov; 170(5):981-985.e1. PubMed ID: 26542508
[TBL] [Abstract][Full Text] [Related]
29. Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.
Torngren K; Ohman J; Salmi H; Larsson J; Erlinge D
Cardiology; 2013; 124(4):252-8. PubMed ID: 23594617
[TBL] [Abstract][Full Text] [Related]
30. Ticagrelor: positive, negative and misunderstood properties as a new antiplatelet agent.
Steiner JB; Wu Z; Ren J
Clin Exp Pharmacol Physiol; 2013 Jul; 40(7):398-403. PubMed ID: 23590223
[TBL] [Abstract][Full Text] [Related]
31. Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
Azmoon S; Angiolillo DJ
Catheter Cardiovasc Interv; 2013 Feb; 81(2):232-42. PubMed ID: 22581463
[TBL] [Abstract][Full Text] [Related]
32. Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents.
Höchtl T; Tentzeris I; Schrör K; Huber K
Fundam Clin Pharmacol; 2012 Feb; 26(1):2-10. PubMed ID: 21831128
[TBL] [Abstract][Full Text] [Related]
33. Contemporary Time Trends in Use of Antiplatelet Agents Among Patients with Acute Coronary Syndrome and Comorbid Diabetes Mellitus or Chronic Kidney Disease.
Desai RJ; Spoendlin J; Mogun H; Gagne JJ
Pharmacotherapy; 2017 Oct; 37(10):1322-1327. PubMed ID: 28833345
[TBL] [Abstract][Full Text] [Related]
34. Safety profile and bleeding risk of ticagrelor compared with clopidogrel.
May CH; Lincoff AM
Expert Opin Drug Saf; 2012 Nov; 11(6):959-67. PubMed ID: 22950441
[TBL] [Abstract][Full Text] [Related]
35. Ticagrelor approved for acute coronary syndrome.
Traynor K
Am J Health Syst Pharm; 2011 Sep; 68(17):1568. PubMed ID: 21856798
[No Abstract] [Full Text] [Related]
36. Clopidogrel: the data, the experience, and the controversies.
Sadanandan S; Singh IM
Am J Cardiovasc Drugs; 2012 Dec; 12(6):361-74. PubMed ID: 23057989
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials.
Roule V; Agueznai M; Sabatier R; Blanchart K; Lemaître A; Ardouin P; Collet JP; Milliez P; Montalescot G; Beygui F
Platelets; 2017 Mar; 28(2):174-181. PubMed ID: 27657930
[TBL] [Abstract][Full Text] [Related]
38. Ticagrelor for acute coronary syndrome?
Drug Ther Bull; 2011 Jun; 49(6):66-8. PubMed ID: 21632607
[TBL] [Abstract][Full Text] [Related]
39. The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.
Bernlochner I; Byrne RA; Kastrati A; Sibbing D
Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):999-1014. PubMed ID: 21878045
[TBL] [Abstract][Full Text] [Related]
40. Current antiplatelet options for NSTE-ACS patients.
Cayla G; Silvain J; O'Connor SA; Collet JP; Montalescot G
QJM; 2012 Oct; 105(10):935-48. PubMed ID: 22543683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
